Tumor News and Research

RSS

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

Fred Hutchinson Cancer Research Center scientists striving for new cancer cures - and the patients who stand to benefit from them - got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single contribution in Fred Hutch's history.

8 Apr 2014

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.

8 Apr 2014

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

8 Apr 2014

Dream team aims to turn pancreatic cancer into treatable disease

UC San Francisco has been selected to join a national "dream team" on pancreatic cancer, part of a project designed to accelerate treatment and discoveries for one of the most deadly forms of cancer.

8 Apr 2014

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

NRAS gene that plays fundamental role in cancer development produces five gene variants, says study

A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought.

8 Apr 2014

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest patients.

8 Apr 2014

Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

Eli Lilly and Company will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.

7 Apr 2014

Study: Ginsenoside Rb1 attenuates neuronal damage following cerebral ischemia

Activated microglia-mediated inflammation promotes neuronal damage under cerebral hypoxic-ischemic conditions, so it is likely that inhibiting hypoxia-induced activation of microglia will alleviate neuronal damage.

7 Apr 2014

Researchers use ultrasound to destroy cancerous tissue in brain

Researchers in Zurich, Switzerland have successfully used focused ultrasound for the first time to non-invasively ablate part of a recurrent glioma tumor through a patient's intact skull.

7 Apr 2014

New insights provide novel therapeutic approach against cancer

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes.

7 Apr 2014

OncoSec Medical to re-launch Phase II cutaneous T-cell lymphoma trial under protocol amendment

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will re-launch its Phase II cutaneous T-cell lymphoma (CTCL) trial under a protocol amendment.

7 Apr 2014

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Oncothyreon Inc. today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).

7 Apr 2014

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

...

7 Apr 2014

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

An examination of the genetic landscape of head and neck cancers indicates that while metastatic and primary tumor cells share similar mutations, recurrent disease is associated with gene alterations that could be exquisitely sensitive to an existing cancer drug.

7 Apr 2014

Research suggests NEDD9 scaffolding protein activates oncogenic signaling pathways in cancer cells, encourages metastases

Researchers from Fox Chase Cancer Center have shown that NEDD9, a scaffolding protein responsible for regulating signaling pathways in the cell, promotes the growth and spread of epithelial ovarian cancer.

7 Apr 2014

Wistar findings suggest link between colon microbiome and genome stability

Colorectal cancer develops in what is probably the most complex environment in the human body, a place where human cells cohabitate with a colony of approximately 10 trillion bacteria, most of which are unknown.

7 Apr 2014

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes.

7 Apr 2014

Genetic screening of cancer can help doctors customize treatments in patients with melanoma

Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

7 Apr 2014

Blood sample could diagnose many types of solid cancers

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.

7 Apr 2014

Tumor News and Research

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

Dream team aims to turn pancreatic cancer into treatable disease

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

NRAS gene that plays fundamental role in cancer development produces five gene variants, says study

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

Study: Ginsenoside Rb1 attenuates neuronal damage following cerebral ischemia

Researchers use ultrasound to destroy cancerous tissue in brain

New insights provide novel therapeutic approach against cancer

OncoSec Medical to re-launch Phase II cutaneous T-cell lymphoma trial under protocol amendment

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

Research suggests NEDD9 scaffolding protein activates oncogenic signaling pathways in cancer cells, encourages metastases

Wistar findings suggest link between colon microbiome and genome stability

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Genetic screening of cancer can help doctors customize treatments in patients with melanoma

Blood sample could diagnose many types of solid cancers

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News